Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra) in Patients With Lenalidomide (Revlimid) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome.

Trial Profile

Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra) in Patients With Lenalidomide (Revlimid) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2013

At a glance

  • Drugs Ezatiostat (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 22 Jan 2013 In order to focus its resources on the registrational programme, Telik has decided to stop further enrollment it its phase II exploratory trials, including this trial, as announced in a company media release.
    • 22 Jan 2013 Status changed from recruiting to active, no longer recruiting based on information reported in a Telik media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top